Current Report Filing (8-k)
July 16 2021 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (date of earliest event reported):
July 15, 2021
iBio,
Inc.
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
001-35023
|
26-2797813
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
8800 HSC Parkway
Bryan, Texas 77807
(Address of principal executive offices and
zip code)
(979) 446-0027
(Registrant’s telephone number including
area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
IBIO
|
NYSE American
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01.
|
Regulation FD Disclosure.
|
On July 15, 2021, iBio, Inc. (the
“Company”) issued a press release announcing that preclinical studies of IBIO-202, its subunit vaccine candidate that targets
the nucleocapsid protein (“N protein”) of SARS-CoV-2, have demonstrated robust antigen-specific, memory T-cell response.
The information in this Item 7.01 and in the press
release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2)
of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1
to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission
made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
The press release attached
as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation
Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.
The Company undertakes
no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from
time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents
with the Securities and Exchange Commission, through press releases or through other public disclosures.
The Company today announced that
preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein (“N protein”) of SARS-CoV-2,
have demonstrated robust antigen-specific, memory T-cell response. A strong, cytotoxic, memory T-cell response was seen in the IBIO-202
immunization data. In addition, T-cell priming was achieved via both intramuscular and intranasal administration, allowing for the further
exploration of multiple routes of administration and their respective benefits. Data from the preclinical studies are attached as Exhibit
99.2.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
The following exhibit is filed with this Current Report on Form 8-K.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
IBIO INC.
|
|
|
Date: July 16, 2021
|
By:
|
/s/ Thomas F. Isett
|
|
|
|
Name:
|
Thomas F. Isett
|
|
|
|
Title:
|
Chairman
and Chief Executive Officer
|
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024